fortune gems tricks

fortune gems tricks NEW YORK (AP) — Angelina Jolie never expected to hit all the notes. But finding the breath of Maria Callas was enough to bring things out of Jolie that she didn’t even know were in her. “All of us, we really don’t realize where things land in our body over a lifetime of different experiences and where we hold it to protect ourselves,” Jolie said in a recent interview. “We hold it in our stomachs. We hold it in our chest. We breathe from a different place when we’re nervous or we’re sad. “The first few weeks were the hardest because my body had to open and I had to breathe again,” she adds. “And that was a discovery of how much I wasn’t.” In Pablo Larraín’s “Maria,” which Netflix released in theaters Wednesday before it begins streaming on Dec. 11, Jolie gives, if not the performance of her career, then certainly of her last decade. Beginning with 2010’s “In the Land of Blood and Honey,” Jolie has spent recent years directing films while prioritizing raising her six children. “So my choices for quite a few years were whatever was smart financially and short. I worked very little the last eight years,” says Jolie. “And I was kind of drained. I couldn’t for a while.” But her youngest kids are now 16. And for the first time in years, Jolie is back in the spotlight, in full movie-star mode. Her commanding performance in “Maria” seems assured of bringing Jolie her third Oscar nomination. (She won supporting actress in 2000 for “Girl, Interrupted.”) For an actress whose filmography might lack a signature movie, “Maria” may be Jolie's defining role. Jolie's oldest children, Maddox and Pax, worked on the set of the film. There, they saw a version of their mother they hadn't seen before. “They had certainly seen me sad in my life. But I don’t cry in front of my children like that,” Jolie says of the emotion Callas dredged up in her. “That was a moment in realizing they were going to be with me, side by side, in this process of really understanding the depth of some of the pain I carry.” Jolie, who met a reporter earlier this fall at the Carlyle Hotel, didn't speak in any detail of that pain. But it was hard not to sense some it had to do with her lengthy and ongoing divorce from Brad Pitt, with whom she had six children. Just prior to meeting, a judge allowed Pitt’s remaining claim against Jolie, over the French winery Château Miraval, to proceed. On Monday, a judge ruled that Pitt must disclose documents Jolie’s legal team have sought that they allege include “communications concerning abuse.” Pitt has denied ever being abusive. The result of the U.S. presidential election was also just days old, though Jolie — special envoy for the United Nations Refugee Agency from 2012 to 2022 – wasn’t inclined to talk politics. Asked about Donald Trump’s win , she responded, “Global storytelling is essential,” before adding: “That’s what I’m focusing on. Listening. Listening to the voices of people in my country and around the world.” Balancing such things — reports concerning her private life, questions that accompany someone of her fame — is a big reason why Jolie is so suited to the part of Callas. The film takes place during the American-born soprano’s final days. (She died of a heart attack at 53 in 1977.) Spending much of her time in her grand Paris apartment, Callas hasn’t sung publicly in years; she’s lost her voice. Imprisoned by the myth she’s created, Callas is redefining herself and her voice. An instructor tells her he wants to hear “Callas, not Maria." The movie, of course, is more concerned with Maria. It’s Larrain’s third portrait of 20th century female icon, following “Jackie” (with Natalie Portman as Jacqueline Kennedy) and “Spencer” (with Kristen Stewart as Princess Diana). As Callas, Jolie is wonderfully regal — a self-possessed diva who deliciously, in lines penned by screenwriter Steven Knight, spouts lines like: “I took liberties all my life and the world took liberties with me.” Asked if she identified with that line, Jolie answered, “Yeah, yeah.” Then she took a long pause. “I’m sure people will read a lot into this and there’s probably a lot I could say but don’t want to feed into,” Jolie eventually continues. “I know she was a public person because she loved her work. And I’m a public person because I love my work, not because I like being public. I think some people are more comfortable with a public life, and I’ve never been fully comfortable with it.” When Larraín first approached Jolie about the role, he screened “Spencer” for her. That film, like “Jackie” and “Maria,” eschews a biopic approach to instead intimately focus on a specific moment of crisis. Larraín was convinced Jolie was meant for the role. “I felt she could have that magnetism,” Larraín says. “The enigmatic diva that’s come to a point in her life where she has to take control of her life again. But the weight of her experience, of her music, of her singing, everything, is on her back. And she carries that. It’s someone who’s already loaded with a life that’s been intense.” “There’s a loneliness that we both share,” Jolie says. “That’s not necessarily a bad thing. I think people can be alone and lonely sometimes, and that can be part of who they are.” Larraín, the Chilean filmmaker, grew up in Santiago going to the opera, and he has long yearned to bring its full power and majesty to a movie. In Callas, he heard something that transfixed him. “I hear something near perfection, but at the same time, it’s something that’s about to be destroyed,” Larraín says. “So it’s as fragile and as strong as possible. It lives in both extremes. That’s why it’s so moving. I hear a voice that’s about to be broken, but it doesn’t.” In Callas’ less perfect moments singing in the film, Larraín fuses archival recordings of Callas with Jolie’s own voice. Some mix of the two runs throughout “Maria.” “Early in the process,” Jolie says, “I discovered that you can’t fake-sing opera.” Jolie has said she never sang before, not even karaoke. But the experience has left her with a newfound appreciation of opera and its healing properties. “I wonder if it’s something you lean into as you get older,” Jolie says. “Maybe your depth of pain is bigger, your depth of loss is bigger, and that sound in opera meets that, the enormity of it.” If Larraín’s approach to “Maria” is predicated on an unknowingness, he's inclined to say something similar about his star. “Because of media and social media, some people might think that they know a lot about Angelina,” he says. “Maria, I read nine biographies of her. I saw everything. I read every interview. I made this movie. But I don’t think I would be capable of telling you who she was us. So if there’s an element in common, it’s that. They carry an enormous amount of mystery. Even if you think that you know them, you don’t.” Whether “Maria” means more acting in the future for Jolie, she's not sure. “There's not a clear map,” she says. Besides, Jolie isn't quite ready to shake Callas. “When you play a real person, you feel at some point that they become your friend,” says Jolie. “Right now, it’s still a little personal. It’s funny, I’ll be at a premiere or I’ll walk into a room and someone will start blaring her music for fun, but I have this crazy internal sense memory of dropping to my knees and crying.” Jake Coyle, The Associated PressLast week, UnitedHealthcare CEO Brian Thompson was shot to death on a New York City sidewalk in what was clearly a thoroughly planned-out attack. Over the next few days, as authorities hunted for the killer, online progressives did not try hard to hide their delight that a millionaire health insurance executive like Thompson was killed. Social media was flooded with posts and videos—with different ranges of subtlety—suggesting that Thompson, at the very least, did not deserve to be mourned because of all the health care his company has denied to poor and working people. Progressives framed the shooting as an act of self-defense on behalf of the working class. Before the alleged killer was caught Monday, they promised not to snitch if they saw the shooter themselves and fantasized about a working-class jury nullifying all charges, leading to other CEOs getting gunned down with impunity if they oversaw price increases. The narrative that these online progressives clearly subscribe to and perpetuate is one where, in the United States, healthcare is a totally unfettered, unregulated industry; where—because of a total lack of government involvement—wealthy CEOs charge whatever prices they want and then refuse to provide customers what they already paid for without facing any bad consequences. The characterization of healthcare and health insurance companies charging absurdly high prices while treating their customers terribly without the risk of losing them is spot on. But the idea that what caused this was a lack of government involvement in the healthcare system is completely delusional. And this delusion conveniently removes all the responsibility progressives bear for the nightmare that is the US healthcare system. Today, healthcare is one of the most heavily government-regulated industries in the economy—right up there with the finance and energy sectors. Government agencies are involved in all parts of the process, from the research and production of drugs, the training and licensing of medical professionals, and the building of hospitals to the availability of health insurance, the makeup of insurance plans, and the complicated payment processes. And that is nothing new. The US government has been intervening heavily in the healthcare industry for over a century. And no group has done more to bring this about than the progressives. It really began, after all, during the Progressive Era, when the American Medical Association maneuvered its way into setting the official accreditation standards for the nation’s “unregulated” medical schools. The AMA wrote standards that excluded the medical approaches of their competitors, which forced half of the nation’s medical schools to close. The new shortage of trained doctors drove up the price of medical services—to the delight of the AMA and other government-recognized doctor’s groups—setting the familiar healthcare affordability crisis in motion. Around the same time, progressives successfully pushed for strict restrictions on the production of drugs and, shortly afterward, to grant drug producers monopoly privileges. After WWII, as healthcare grew more expensive, the government used the tax code to warp how Americans paid for healthcare. Under President Truman, the IRS made employer-provided health insurance tax deductible while continuing to tax other means of payment. It didn’t take long for employer plans to become the dominant arrangement and for health insurance to morph away from actual insurance into a general third-party payment system. These government interventions restricting the supply of medical care and privileging insurance over other payment methods created a real affordability problem for many Americans. But the crisis didn’t really start until the 1960s when Congress passed two of the progressive’s favorite government programs—Medicare and Medicaid. Initially, industry groups like the AMA opposed Medicare and Medicaid because they believed the government subsidies would deteriorate the quality of care. They were right about that, but what they clearly didn’t anticipate was how rich the programs would make them. Anyone who’s taken even a single introductory economics class could tell you that prices will rise if supply decreases or demand increases. The government was already keeping the supply of medical services artificially low—leading to artificially high prices. Medicare and Medicaid left those shortages in place and poured a ton of tax dollars into the healthcare sector—significantly increasing demand. The result was an easily predictable explosion in the cost of healthcare. Fewer and fewer people could afford healthcare at these rising prices, meaning more people required government assistance, which meant more demand, causing prices to grow faster and faster. Meanwhile, private health “insurance” providers were also benefiting from the mounting crisis. In a free market, insurance serves as a means to trade risk. Insurance works well for accidents and calamities that are hard to predict individually but relatively easy to predict in bulk, like car accidents, house fires, and unexpected family deaths. Health insurance providers were already being subsidized by all the taxes on competing means of payment, which allowed their plans to grow beyond the typical bounds of insurance and begin to cover easily-predictable occurrences like annual physicals. And, as the price of all of these services continued to shoot up, the costs of these routine procedures were becoming high enough to resemble the costs of emergencies—making consumers even more reliant on insurance. With progressives cheering on, the political class used government intervention to create a healthcare system that behaves as if its sole purpose is to move as much money as possible into the pockets of healthcare providers, drug companies, hospitals, health-related federal agencies, and insurance providers. But the party could not last forever. As the price of healthcare rose, the price of health insurance rose, too. Eventually, when insurance premiums grew too high, fewer employers or individual buyers were willing to buy insurance, and the flow of money into the healthcare system started to falter. The data suggests that that tipping point was reached in the early 2000s. For the first time since the cycle began back in the 1960s, the number of people with health insurance began to fall each year. Healthcare providers—who had seemingly assumed that the flow of money would never stop increasing—began to panic. Then came Barack Obama. Obama’s seminal legislative accomplishment—the Affordable Care Act, or Obamacare—can best be understood as a ploy by healthcare providers and the government to keep the party going. Obamacare required all fifty million uninsured Americans to obtain insurance, and it greatly expanded what these “insurance” companies covered. Demand for healthcare shot back up, and the vicious cycle started back up again—which is why the bill enjoyed so much support from big corporations all across the healthcare industry. Before it was passed, economists were practically screaming that the Affordable Care Act would make care less affordable by raising premiums and healthcare prices while making shortages worse. Progressives dismissed such concerns as Reagan-era “free market fundamentalist” propaganda. But that is exactly what happened . Now, the affordability crisis is worse than ever as prices reach historic levels. And, because Obamacare brought American healthcare much closer to a single-payer system, the demand for healthcare far exceeds the supply of healthcare—leading to deadly shortages. There are literally not enough resources or available medical professionals to treat everyone who can pay for care. Also, the tax code and warped “insurance” market protect these providers from competition—making it almost impossible for people to switch to a different provider after their claims are unfairly denied. If it were simply greed, denying customers who already paid would be a feature in all industries. But it’s not. It requires the kind of policy protections progressives helped implement. And on top of all that, despite paying all this money, Americans are quickly becoming one of the sickest populations on Earth. This is one of the most pressing problems facing the country. A problem that requires immediate, radical change to solve. But it also requires an accurate and precise diagnosis—something that, this week, progressives demonstrated they are incapable of making. Related Articles Commentary | John Stossel: Your tax dollars not at work Commentary | After so many years of failure, time’s up for California Democrats Commentary | Vince Fong: We don’t need Newsom to lecture us. We need him to listen to us. Commentary | Deregulation rather than fossil fuel controls needed to fix California insurance market Commentary | The FBI has been political from the start The American progressive movement is responsible for providing the political class the intellectual cover they needed to break the healthcare market and transform the entire system into a means to transfer wealth to people like Brian Thompson. Now, they want to sit back, pretend like they’ve never gotten their way, that the government has never done anything with the healthcare market, and that these healthcare executives just popped up and started doing this all on their own—all so they can celebrate him being gunned down in the street. It’s disgusting. Brian Thompson acted exactly like every economically literate person over the last fifty years has said health insurance CEOs would act if progressives got their way. If we’re ever going to see the end of this century-long nightmare, we need to start listening to the people who have gotten it right, not those who pretend they are blameless as they fantasize online about others starting a violent revolution. Connor O’Keeffe ( @ConnorMOKeeffe ) produces media and content at the Mises Institute. This commentary is republished with permission from the Mises Institute.

A rape allegation against rapper Jay-Z, whose company Roc Nation has produced some of the NFL’s entertainment presentations including the Super Bowl halftime show, will not affect the league’s relationship with the music mogul. “We’re aware of the civil allegations and Jay-Z’s really strong response to that,” NFL (National Football League) commissioner Roger Goodell said on Wednesday after the conclusion of the league’s winter meetings. “We know the litigation is happening now. From our standpoint, our relationship is not changing with them, including our preparations for the next Super Bowl.” A woman who previously sued musician Sean “Diddy” Combs, alleging she was raped at an awards show after-party in 2000 when she was 13 years old, amended the lawsuit on Sunday to include a new allegation that Jay-Z was also at the party and participated in the sexual assault. Jay-Z, real name Shawn Carter, said the rape allegation made against him is part of an extortion attempt. The 24-time Grammy Award winner called the allegations “idiotic” and “heinous in nature” in a statement released by Roc Nation. The NFL teamed up with Jay-Z’s Roc Nation in 2019 for events and social activism. The league and the entertainment company extended their partnership a few months ago. Kendrick Lamar will perform the Super Bowl halftime show at The Caesars Superdome in New Orleans on February 9. Roc Nation and Emmy-winning producer Jesse Collins will serve as co-executive producers of the halftime show. Beyonce, who is married to Jay-Z, will perform at halftime of the Baltimore Ravens-Houston Texans game at Christmas. “I think they’re getting incredibly comfortable not just with the Super Bowl but other events they’ve advised us on and helped us with,” Mr Goodell said. “They’ve been a big help in the social justice area to us on many occasions. They’ve been great partners.”

NEW YORK--(BUSINESS WIRE)--Nov 22, 2024-- Attentive , the AI-powered mobile marketing platform, today announced it ranked #242 on the Deloitte Technology Fast 500 TM, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30 th year. Attentive’s rapid growth, marked by a 493% increase over the past three years, can be attributed to its native personalization solutions driven by artificial intelligence and machine learning to deliver one-on-one communications at scale. "Today's generic online shopping experience will soon be outdated," says Amit Jhawar, CEO of Attentive. "The future is about personalizing every consumer interaction with AI, and Attentive is poised to lead this transformation. The continued recognition by Deloitte is a testament of seeing more global brands reset their technical stack to take advantage of Attentive’s modern capabilities that enable smarter, more dynamic conversations that lead to measurable growth." Attentive continues to deliver significant value for brands in both revenue and business growth. According to the Total Economic Impact TM of Attentive SMS Marketing, a commissioned study conducted by Forrester Consulting , the composite Attentive customer experienced total benefits of $10.11 million (USD) over three years, with an 181% return on investment. Attentive has been named to the Deloitte Technology Fast 500 award for four consecutive years. The company achieved several additional significant milestones, including: In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America. About Attentive Attentive® is the AI-powered mobile marketing platform transforming the way brands personalize consumer engagement. Attentive enables marketers to craft tailored journeys for every subscriber, driving higher recurring revenue and maximizing campaign performance. Activating real-time data from multiple channels and advanced AI, the platform personalizes content, tone, and timing to help brands deliver 1:1 messages that truly resonate. With a top-rated customer success team recognized on G2, Attentive partners with marketers to provide strategic guidance and optimize SMS and email campaigns. Trusted by leading global brands like GUESS, Urban Outfitters, and Steve Madden, Attentive ensures enterprise-grade compliance and deliverability, supporting trillions of interactions across more than 70 industries. To learn more or request a demo, visit www.attentive.com or follow us on LinkedIn , X (formerly Twitter), or Instagram . About Deloitte Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an impact that matters by creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as they build their future . Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 460,000 people worldwide connect for impact at www.deloitte.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20241122866813/en/ PR Contact: Annie Lee, Attentive,press@attentive.com KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: DATA MANAGEMENT TECHNOLOGY PROFESSIONAL SERVICES MARKETING COMMUNICATIONS OTHER TECHNOLOGY DIGITAL MARKETING SOFTWARE ARTIFICIAL INTELLIGENCE MOBILE/WIRELESS FINANCE SOURCE: Attentive Copyright Business Wire 2024. PUB: 11/22/2024 01:07 PM/DISC: 11/22/2024 01:06 PM http://www.businesswire.com/news/home/20241122866813/en

PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023 . The injunction, which the Court said it will enter in January 2025 , is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023 . Such customers can continue to purchase GeoMx reagents for use with existing GeoMx instruments for purposes of continuing their ongoing research. The Court found that making such an exception for ongoing research strikes a "workable balance between protecting the patentee's rights and protecting the public from the injunction's adverse effects." In addition, the Court affirmed the $31 million damages awarded by the November 2023 jury verdict, as well as supplemental damages and interest that will be added to the total damages when final judgment is entered. "Today's decision helps to safeguard our decade-long investment in innovation and ensures we can continue to develop groundbreaking technologies that help our customers revolutionize science," said Eric Whitaker , Chief Legal Officer at 10x Genomics. "10x exists to fuel scientific progress – not stifle it – and that is why we've done our utmost to ensure this injunction was structured to protect both our intellectual property and existing GeoMx customers' ongoing research." The Court recognized the harm NanoString's infringing conduct caused 10x when it wrote in its ruling, "Having been careful not to license its technology, 10x suffers when it proclaims itself as an innovator in spatial genomics but a competitor is using the same innovative, patented technology." Today's Court decision follows a November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys. During the trial, the jury heard testimony from the sole inventor of the patents, Illumina co-founder Mark Chee , and NanoString CEO Brad Gray and NanoString CSO Joe Beechem. After hearing all of the evidence, the jury determined that all seven patents had been infringed by NanoString, that each patent was valid, that NanoString willfully infringed those patents and that monetary damages were owed to 10x for the infringement of all seven patents. In affirming the jury's finding that NanoString willfully infringed, the Court relied on the evidence showing that NanoString knew or was willfully blind that its acts would cause infringement of 10x's rights. The asserted patents in Case No. 21-cv-653-MFK include (a) U.S. Patent No. 10,472,669; (b) U.S. Patent No. 10,961,566; (c) U.S. Patent No. 10,983,113; (d) U.S. Patent No. 10,996,219; (e) U.S. Patent No. 11,001,878; (f) U.S. Patent No. 11,008,607 and (g) U.S. Patent No. 11,293,917. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter) . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and remedies as well as possible outcomes of litigation. These forward-looking statements do not reflect that our success will depend on our ability to obtain, maintain and protect our intellectual property rights, intellectual property litigation could be expensive, time-consuming, unsuccessful and could interfere with our ability to develop, manufacture and commercialize our products or technologies, litigation outcomes are unpredictable or there may be changes in our litigation strategy. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, our website ( www.10xgenomics.com ), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Contacts Investors: investors@10xgenomics.com Media: media@10xgenomics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/us-district-court-awards-10x-genomics-permanent-injunction-in-patent-infringement-lawsuit-against-bruker-corporations-geomx-products-302338627.html SOURCE 10x Genomics, Inc. Best trending stories from the week. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. You may occasionally receive promotions exclusive discounted subscription offers from the Roswell Daily Record. Feel free to cancel any time via the unsubscribe link in the newsletter you received. You can also control your newsletter options via your user dashboard by signing in.Bashar Barhoum woke in his prison cell in Damascus at dawn, thinking it would be the last day of his life. The 63-year-old writer was supposed to have been executed after being imprisoned for seven months. But he soon realized the men at the door weren’t from former Syrian President Bashar Assad’s notorious security forces, ready to take him to his death. Instead, they were rebels coming to set him free. As the insurgents swept across Syria in just 10 days to bring an end to the Assad family’s 50-year rule Dec. 8, they broke into prisons and security facilities to free political prisoners and many of the tens of thousands of people who disappeared since the conflict began back in 2011. Barhoum was one of those freed who were celebrating in Damascus. “I haven’t seen the sun until today,” Barhoum told The Associated Press after walking in disbelief through the streets of Damascus. “Instead of being dead tomorrow, thank God, he gave me a new lease of life.” Barhoum couldn’t find his cellphone and belongings in the prison, so he set off to find a way to tell his wife and daughters that he’s alive. Videos shared widely across social media showed dozens of prisoners running in celebration after the insurgents released them, some barefoot and others wearing little clothing. One of them screams in celebration after he finds out that the government has fallen. Syria’s prisons have been infamous for their harsh conditions. Torture is systemic, say human rights groups, whistleblowers and former detainees. Secret executions have been reported at more than two dozen facilities run by Syrian intelligence, as well as at other sites. In 2013, a Syrian military defector, known as “Caesar,” smuggled out over 53,000 photographs that human rights groups say showed clear evidence of rampant torture, but also disease and starvation in Syria’s prison facilities. Syria’s feared security apparatus and prisons did not only serve to isolate Assad’s opponents, but also to instill fear among his own people, said Lina Khatib, Associate Fellow in the Middle East and North Africa program at the London think tank Chatham House. “Anxiety about being thrown in one of Assad’s notorious prisons created wide mistrust among Syrians,” Khatib said. “Assad nurtured this culture of fear to maintain control and crush political opposition.” Just north of Damascus, in the Saydnaya military prison known as the “human slaughterhouse,” female detainees, some with their children, screamed as men broke the locks off their cell doors in the early hours Sunday as insurgents entered the city. Amnesty International and other groups say that dozens of people were secretly executed every week in Saydnaya, estimating that up to 13,000 Syrians were killed between 2011 and 2016. “Don’t be afraid ... Bashar Assad has fallen! Why are you afraid?” said one of the rebels as he tried to rush streams of women out of their jam-packed tiny cells. Tens of thousands of detainees have so far been freed, said Rami Abdurrahman of the Syrian Observatory for Human Rights, a Britain-based pro-opposition war monitor. Over the course of 10 days, insurgents freed prisoners in cities including Aleppo, Homs, Hama and Damascus. Omar Alshogre, who was detained for three years and survived relentless torture, watched in awe from his home far from Syria as videos showed dozens of detainees fleeing. “A hundred democracies in the world had done nothing to help them, and now a few military groups came down and broke open prison after prison,” Alshogre, a human rights advocate who now resides in Sweden and the U.S., told The Associated Press. Meanwhile, families of detainees and the disappeared skipped celebrations of the downfall of the Assad dynasty. Instead, they waited outside prisons and security branch centers, hoping their loved ones would be there. They had high expectations for the newcomers who will now run the battered country. “This happiness will not be completed until I can see my son out of prison and know where he is,” said Bassam Masri. “I have been searching for him for two hours. He has been detained for 13 years,” since the start of the Syrian uprising in 2011. Rebels struggled to control the chaos as crowds gathered by the Court of Justice in Damascus. Heba, who gave only her first name while speaking to the AP, said she was looking for her brother and brother-in-law who were detained while reporting a stolen car in 2011 and hadn’t been seen since. “They took away so many of us,” said Heba, whose mother’s cousin also disappeared. “We know nothing about them ... They (the Assad government) burned our hearts.” Get local news delivered to your inbox!FILE - The Rikers Island jail complex is shown in the Bronx borough of New York, on Tuesday, May 7, 2024. (AP Photo/Ted Shaffrey, File) AP The Associated Press NEW YORK (AP) — A judge on Wednesday found New York City in contempt for failing to staunch violence and brutality at its jails, a scathing ruling that puts the troubled Rikers Island jail complex on the verge of a federal takeover. In a written ruling, U.S. District Judge Laura Taylor Swain in Manhattan said the city had placed incarcerated people in “unconstitutional danger” by failing to comply with 18 separate provisions of court orders pertaining to security, staffing, supervision, use of force and the safety of young detainees. The long-squalid conditions have worsened significantly in the nine years since the city settled abuse and violence claims, she wrote, exacerbated by jail leadership’s “unwillingness or inability” to implement ordered reforms. As a result, Swain ordered the city and lawyers suing on behalf of detainees to confer with a court-appointed monitor on a proposed framework for a federal receivership — an extraordinary intervention that would cede city control of one of the nation’s largest, most notorious jail systems. Mayor Eric Adams, who has vehemently opposed a federal takeover, said on Wednesday that the city had made “significant progress towards addressing the decades-long neglect and issues on Rikers Island.” “We are proud of our work, but recognize there is more to be done and look forward to working with the federal monitoring team on our shared goal of continuing to improve the safety of everyone in our jails,” his statement continued. But in her ruling, Swain found the administration’s efforts were “insufficient to turn the tide within a reasonable period.” The city appears to have acted in bad faith at times in its failure to comply with court-ordered reforms, repeatedly “withholding essential information” from the monitor, she wrote. “The Court is inclined to impose a receivership: namely, a remedy that will make the management of the use of force and safety aspects of the Rikers Island jails ultimately answerable directly to the Court,” Swain wrote, ordering the sides to provide her by Jan. 14 a plan for an “efficient, effective receivership.” The 65-page ruling stemmed from litigation that started more than a decade ago with allegations by a public defender organization, the Legal Aid Society, and others that the city’s Department of Correction had engaged in a pattern of excessive and unnecessary force. The Legal Aid Society and law firm Emery Celli Brinckerhoff Abady Ward & Maazel LLP hailed the “historic decision” and said it “will finally create a pathway for reform that can protect those who have been failed” by jail leadership. “The court’s recognition that the current structure has failed, and that receivership free from political and other external influences is the path forward, can ensure that all New Yorkers, regardless of incarceration status, are treated with the respect and dignity guaranteed to them under the law,” they said. In a separate statement, Benny Boscio, the president of the union representing correction officers, claimed the ruling was based on an “erroneous narrative,” adding that jail staff had been “defunded, short staffed, scapegoated and handcuffed” by city lawmakers and the federal monitor. For now, barring further action from Swain, the city remains in control of its jails. The jail complex, which is housed on a hard-to-reach island in the East River, has long suffered from rampant disorder and neglect. But rates of violence, use of force, self-harm, and deaths in custody in city jails have gotten “demonstrably worse” since the city and parties agreed in October 2015 to a settlement, consent decree and the appointment of a federal monitor, Swain said. “Worse still, the unsafe and dangerous conditions in the jails, which are characterized by unprecedented rates of use of force and violence, have become normalized despite the fact that they are clearly abnormal and unacceptable,” the judge wrote. RECOMMENDED • syracuse .com US seeks to break up Google, forcing Chrome sale as part of monopoly punishment Nov. 21, 2024, 11:34 a.m. Businessman behind huge Trump sign in Upstate NY running to fill Stefanik’s seat Nov. 24, 2024, 6:52 a.m. Nineteen people died in custody at Rikers Island in 2022. Nine more died in 2023, and five died in the first eight months of this year. At the same time, rates of stabbings and slashings, fights, assaults on staff “remain extraordinarily high,” Swain said. There has been “no substantial reduction in the risk of harm currently facing those who live and work in the Rikers Island jails,” the judge wrote. Under a plan approved by the city council in 2019, New York City is legally required to shutter Rikers Island and replace it with four smaller and more modern jails by 2027. But as the jail population has grown in recent years, Adams, a Democrat, has voiced resistance to the closure, urging lawmakers to come up with a “Plan B.” Earlier this year, the city’s budget director acknowledged that officials would likely not meet the mandated deadline.Shares of Park Hotels & Resorts Inc. ( NYSE:PK – Get Free Report ) have earned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $18.09. A number of equities analysts have recently issued reports on the stock. Compass Point reduced their target price on shares of Park Hotels & Resorts from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Wells Fargo & Company decreased their price target on Park Hotels & Resorts from $17.00 to $14.50 and set an “equal weight” rating on the stock in a report on Friday, September 13th. Bank of America dropped their price objective on Park Hotels & Resorts from $17.00 to $16.50 and set a “neutral” rating for the company in a report on Monday, October 21st. StockNews.com cut shares of Park Hotels & Resorts from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. Finally, UBS Group boosted their price target on shares of Park Hotels & Resorts from $14.00 to $15.00 and gave the stock a “neutral” rating in a research note on Monday, November 18th. Get Our Latest Stock Report on Park Hotels & Resorts Institutional Inflows and Outflows Park Hotels & Resorts Stock Performance NYSE:PK opened at $15.05 on Tuesday. The stock has a market capitalization of $3.11 billion, a P/E ratio of 9.59, a price-to-earnings-growth ratio of 0.81 and a beta of 2.02. The company has a current ratio of 1.51, a quick ratio of 1.51 and a debt-to-equity ratio of 1.24. Park Hotels & Resorts has a 1 year low of $13.23 and a 1 year high of $18.05. The firm has a 50 day moving average of $14.43 and a 200-day moving average of $14.75. Park Hotels & Resorts ( NYSE:PK – Get Free Report ) last posted its quarterly earnings data on Tuesday, October 29th. The financial services provider reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.21). Park Hotels & Resorts had a return on equity of 9.63% and a net margin of 12.66%. The business had revenue of $649.00 million during the quarter, compared to analyst estimates of $646.15 million. During the same period in the prior year, the firm posted $0.51 EPS. Park Hotels & Resorts’s revenue for the quarter was down 4.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Park Hotels & Resorts will post 2.09 EPS for the current fiscal year. About Park Hotels & Resorts ( Get Free Report Park is one of the largest publicly traded lodging REITs with a diverse portfolio of market-leading hotels and resorts with significant underlying real estate value. Park's portfolio currently consists of 43 premium-branded hotels and resorts with over 26,000 rooms primarily located in prime city center and resort locations. Featured Articles Receive News & Ratings for Park Hotels & Resorts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Park Hotels & Resorts and related companies with MarketBeat.com's FREE daily email newsletter .

Arcadium Lithium Announces Shareholder Approval of Proposed Rio Tinto Transaction and Provides Regulatory UpdateHow Revolutionary Trends Will Shape the Future of Global Travel in 2025: New Report Highlights